

IN THE CLAIMS:

803 B1 > 1. (amended) [Vaccine] A vaccine for the prevention of *Campylobacter* colonisation in animals, characterised in that said vaccine comprises antiserum raised against a flagellaless *Campylobacter* strain .

AS 2. (amended) [Vaccine] A vaccine according to claim 1, characterised in that the flagellaless *Campylobacter* strain is *Campylobacter jejuni*.

3. (amended) [Vaccine] A vaccine according to claim 2, characterised in that the flagellaless *Campylobacter jejuni* strain is strain R2.

4. (amended) [Antigenic] An antigenic protein of *Campylobacter* having a molecular weight of 97 kD (+/-5kD), characterised in that it is visible in a Western blot of *Campylobacter jejuni* protein after incubation of said Western blot with antibodies against a flagellaless mutant of *Campylobacter jejuni* and that it is not visible after incubation of said blot with antibodies against wild type *Campylobacter jejuni*.

5. (amended) [Antigenic] An antigenic protein of *Campylobacter* having a molecular weight of 60 kD (+/-5kD), characterised in that it is visible in a Western blot of *Campylobacter jejuni* protein after incubation of said Western blot with antibodies

against a flagellaless mutant of *Campylobacter jejuni* and that it is not visible after incubation of said blot with antibodies against wild type *Campylobacter jejuni*.

6. (amended) [Antigenic] An antigenic protein of *Campylobacter* having a molecular weight of 13 kD (+/-3kD), characterised in that it is visible in a Western blot of *Campylobacter jejuni* protein after incubation of Western blot with antibodies against a flagellaless mutant of *Campylobacter jejuni* and that it is not visible after incubation of said blot with antibodies against wild *Campylobacter jejuni*.

7. (amended) [Antigenic] An antigenic protein according to claim 4 [,5 or 6] for use in a vaccine.

8. (amended) Use of antigenic protein as defined in claim 4 [,5 or 6] for the manufacturing of a pharmaceutical composition for combating *Campylobacter jejuni* colonisation.

9. (amended) [Vaccine] A vaccine for the prevention of *Campylobacter jejuni* colonisation in poultry, characterised in that said vaccine comprises antibodies against the antigenic protein according to claim 4 [,5 or 6].

10. (amended) [Vaccine] A vaccine for the prevention of *Campylobacter jejuni* colonisation in poultry, characterised in

that said vaccine comprises an antigenic protein according to claim 4 [, 5 or 6].

11. (amended) Use of antibodies against a flagellaless *Campylobacter* strain, or against the antigenic protein of claim 4 [, 5 or 6] for the preparation of a vaccine against *Campylobacter* colonisation in animals.

12. (amended) [Method] A method for the preparation of a vaccine according to [any of the claims 1-3 or 9] claim 1, characterised in that said method comprises raising antiserum against antigenic material of a flagellaless *Campylobacter* strain in a host animal followed by isolating the antiserum of the host animal.

13. (amended) [Method] A method for the preparation of a vaccine according to claim 9, characterised in that said method comprises growing antibody producing cells and harvesting the antibodies.

14. (amended) [Method] A method for the preparation of a vaccine according to claim 10, characterised in that said method comprises admixing a protein according to [any of the claims 4-6] claim 4 and a pharmaceutically acceptable carrier.

---

REMARKS

Claims 1 - 14 are amended. It is believed that claims 1 - 14 recite a patentable improvement in the art. Favorable